Brain and leptomeningeal metastases are common in breast cancer patients and our current treatments are ineffective. Reovirus type 3 is a replication competent, naturally occurring virus that usurps the activated Ras-signaling pathway (or an element thereof) of tumor cells and lyses them but leaves normal cells relatively unaffected. In this study we evaluated reovirus as an experimental therapeutic in models of central nervous system (CNS) metastasis from breast cancer. We found all breast cancer cell lines tested were susceptible to reovirus, with 450% of these cells lysed within 72 h of infection. In vivo neurotoxicity studies showed only mild local inflammation at the injection site and mild communicating hydrocephalus with neither diffuse encephalitis nor behavioral abnormalities at the therapeutically effective dose of reovirus (intracranial) (ie 10 7 plaque-forming units) or one dose level higher. In vivo, a single intratumoral administration of reovirus significantly reduced the size of tumors established from two human breast cancer cell lines and significantly prolonged survival. Intrathecal administration of reovirus also remarkably prolonged survival in an immunocompetent racine model of leptomeningeal metastases. These data suggest that the evaluation of reovirus as an experimental therapeutic for CNS metastases from breast cancer is warranted.
Introduction
Brain metastases are common and occur in approximately 30% of breast cancer patients. [1] [2] [3] [4] For many breast cancer patients the central nervous system (CNS) is the only site of relapse. 5 The median survival of patients with brain or leptomeningeal metastasis is only a few weeks or months and survivals as long as 1 year are uncommon. 5 Clearly novel treatments are desperately needed for this disease.
Oncolytic viruses are viruses that infect and kill tumor cells but leave normal cells relatively unaffected. In contrast to gene therapy, they are directly cytotoxic (infection produces cell lysis and death) rather than delivering a gene that has the therapeutic effect. Since a major limitation of gene therapy has been the very restricted intratumoral (i.t.) distribution of the gene product, the use of replication competent oncolytic viruses is an attractive alternative. As infectious agents, they give rise to progeny virus particles that are capable of disseminating and infecting other susceptible tumor cells. The number of oncolytic viruses is expanding 6 and many have shown sufficient promise to be evaluated in clinical trials. [7] [8] [9] [10] However, only one oncolytic virus (herpes simplex virus) has been studied as an experimental treatment for brain metastases 11, 12 and there are no reports in models of leptomeningeal cancer.
Reovirus (respiratory, enteric, orphan) is a doublestranded RNA virus commonly isolated from the respiratory/gastrointestinal tracts of humans. It is not known to cause disease in humans (hence the designation 'orphan') but causes a lethal infection in neonatal 13 and severe combined immunodeficiency (SCID) mice. 14 It does not produce disease in adult, immunocompetent animals. 15 At least two receptors exist for reovirus, the ubiquitously expressed sialic acid 16, 17 and junction adhesion molecule (JAM). 18 Reovirus preferentially infects and lyses tumor cells but not normal cells 19 by usurping the activated Ras-signaling pathway (markedly upregulated in tumor cells but not in normal cells) for replication. [20] [21] [22] The restriction of reovirus replication in untransformed (normal) cells is due to the activation of the double-stranded RNA-activated protein kinase (PKR) by early viral transcripts, which blocks translation of viral proteins by inhibiting eIF2-a. 22 Activated Ras (or an activated element of the Ras pathway) inhibits (or reverses) PKR activation and this is believed to allow viral protein synthesis and lytic infection to occur. Reovirus has been studied as an experimental therapeutic agent in several cancer models including breast cancer and primary brain tumors. [23] [24] [25] [26] [27] [28] [29] [30] The rationale for investigating this novel therapeutic approach in brain metastases from breast cancer is that, although activating mutations of Ras are infrequent in breast cancer, Ras-signaling pathways are activated via upstream signaling. For example, a member of the EGFR family, Her-2 (Neu/ErbB-2) is amplified and overexpressed in approximately 30% of breast cancer patients. [31] [32] Furthermore, Her-2 signals through Ras, which in turn signals through the ERK/MAP kinase pathway. 33 A number of other receptor 34 or nonreceptor 35 tyrosine kinases that signal through Ras pathways are also activated in breast cancer. Hence, breast cancer cells may create a permissive environment for infection and cell killing by reovirus. In this study, we evaluated reovirus as an experimental therapeutic against brain and leptomeningeal metastases from breast cancer.
Materials and methods

Cell lines and virus
Eight established breast cancer cell lines (HTB129 (MDA-MB435S), HTB132 (MDA-MB-468), 13762MATBIII, HTB19, ZR75-1, MCF-7, SKBR3 and HTB26) and two normal mammary cell lines (HTB124 and HTB125) were purchased from the American Type Culture Collection (Manassas, VA, USA). HTB124 cell line (from a patient with a genetic predisposition to breast cancer) and the HTB125 cell line were generated from normal breast tissue. All cell lines except HTB125 were grown in Dulbecco's modified Eagle's medium/F12 (Hybri-care, American Type Culture Collection, Manassas, VA, USA) containing 10% fetal bovine serum (FBS) at 371C in a humidified 5% CO 2 incubator. HTB125 cells were maintained in Dulbecco's modified Eagle's medium/ F12 containing 20% FBS, 30 ng/ml EGF, 1 mM oxalacetic acid, and 0.2 U/ml crystalline insulin. All cells were passaged when they reached approximately 80% confluence, harvested (except for suspension cells 13762MATBIII) by trypsin treatment, and re-plated in medium. Each cell line was tested routinely for Mycoplasma contamination. All cell lines were characterized for killing by live virus (LV), with dead virus (DV) or no virus (ie, phosphate-buffered saline (PBS)) as controls, at concentrations from 1 to 1000 plaque-forming units (PFUs)/cell. Cell viability was measured at 48-72 h by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoium bromide. Reovirus serotype 3 (strain Dearing) was grown and purified as previously described. 19, 22, 24, 25 Reovirus labeled with [ 35 S]methionine was also grown and purified as previously described. 19, 22, 24, 25 The plaque-forming unit (PFU) ratio for purified reovirus was typically 100/1. DV was prepared by exposing LV to ultraviolet (UV) light for 45-60 min.
Transfection of breast cancer cells with green fluorescent protein (GFP)
FuGene transfection reagent (Roche Diagnostic Co., Indianapolis, USA) and GFP protein vector (Clontech, USA) were used for transfection of breast cancer cells with GFP, as previously described. 25 Transfected cells were selected for G418 antibiotic resistance (500 mg/ml) and identified by fluorescent microscopy. GFP expression was 495% as determined by FACs.
Radiolabeling of reovirus-infected cells and preparation of lysates
Sixty-Seventy percent confluent monolayers of cell lines were infected with reovirus (multiplicity of infection (MOI) of approximately 40 PFUs/cell). At 12 or 36 h after infection, culture media was replaced with methioninefree DMEM containing 10% dialyzed FBS and 50 mCi/ml of [ 35 S]methionine. Cells were incubated for an additional 12 or 36 h at 371C. The cells were then washed in PBS and lysed with PBS containing 1% Triton X-100, 0.5% sodium deoxycholate, and 1 mM EDTA. The nuclei were then removed by centrifugation at 6000 g for 10 min at 41C, and the supernatants were stored at À801C.
Immunoprecipitation
Immunoprecipitation of 35 S-labeled reovirus-infected cell lysates with a polyclonal antireovirus serotype 3 serum was performed as previously described. 24, 25 Immunohistochemistry Cells grown on chamber slides were infected with reovirus (MOI of 40 PFUs/cell) or DV. At 48 h after infection, the cells were fixed in 4% paraformaldehyde for 10 min and followed by four washes with PBS. The cells were then exposed to the primary antibody (rabbit polyclonal antireovirus type 3 serum diluted 1/1000 in PBS containing 2% BSA) for 1 h at room temperature. After three washes with PBS, the cells were exposed to the secondary antibody (goat anti-rabbit immunoglobulin IgG (whole molecule) fluorescein isothiocyanate (FITC) conjugate diluted 1/100 in PBS containing 2% BSA) for 1 h at room temperature. The cells were then counterstained with 4 0 ,6 0 -diamidino-2-phenylindole hydrochloride (DAPI) (Sigma, USA) for 10 min. Finally, the cells were washed three more times with PBS, mounted on slides in with gelvatol, and viewed with a Zeiss Axiophot microscope mounted with a Carl Zeiss camera (Carl Zeiss Inc., Thornwood, NY, USA). For paraffin slides from animal tissues, sections were de-waxed with xylene and rehydrated with 100, 95, 70, 50 and 25% ethanol sequentially prior to fixation with 4% paraformaldehyde. The biotinylated anti-rabbit IgG (Vector Lab., CA, USA) was used as a secondary antibody. An ABC immunohistochemistry Kit (Vector Lab., CA, USA) was applied to carry out immunostaining according to the Kit protocol. For glial fibrillary acidic protein (GFAP) staining, brains were sliced frozen (40 mm) and immunohistochemistry was performed using a mouse monoclonal anti-GFAP antibody (Sigma-Aldrich, Oakville, Ontario, Canada), biotinylated goat anti-mouse IgG (Jackson ImmunoResearch Inc., BIO/CAN Scientific, Mississauga, ON, Canada) and avidin-HRP (Vector Lab., CA, USA).
Animals
CD-1 nude mice (female, 6-8 weeks old) and Fischer 344 inbred rats (female, body weight 180-200 g) were purchased from Charles River Canada (Constant, Canada). The animals were housed in shoebox cages, in groups of three to five in a vivarium maintained on a 12-h light/dark schedule with a temperature of 22711C and a relative , 10 8 , 10 9 PFU/ mouse) using a stereotactic apparatus (Kopf Instruments, Tujanga, CA, USA), as we described previously. 24, 25 Animals were followed for up to 70 days. Animals losing X20% body weight or having other unacceptable symptoms were killed as per our Institutional Animal Care Guidelines. Brains and major organs were taken out and processed for histological examination. The maximum tolerated dose (MTD) and median lethal dose (LD 50 ) were then determined. We selected one dose level below the MTD for the following therapeutic experiments in vivo in nude mice.
The Morris water maze test (MWMT)
CD-1 nude mice were inoculated i.c. using different doses (10 7 , 10 8 and 10 9 PFUs/mouse) of LV, DV or were untreated. At 70 days after infection, animals were then perfused, killed and the brains and major organs were processed for histologic analysis.
Mice were evaluated with Morris water maze 10 days before killing (ie day 60 after viral administration). Since all but one of the mice who received 10 9 PFUs/mouse died, only animals which received LV (10 7 and 10 8 PFUs/ mouse) or DV i.c. were subjected to the behavioral assay. Healthy nonoperated CD-1 nude mice were used as normal controls. The Morris water maze was performed as described [36] [37] [38] [39] with minor modifications. Briefly, a large round black tank (125 cm in diameter and 35 cm in height) was filled with water (22-231C) to a depth of 20 cm. The tank was surrounded by colorful shower curtains, which are thought to provide visual cues for the swimming mice. A square black platform (12 Â 12 cm) was submerged 1.5-2 cm below the water level and placed in one of the quadrants. Mice were then released into the tank from four randomly selected positions and allowed to swim around the tank (for p60 s) until they encountered the platform. Each mouse was allowed four trials (referred as a trial block) every day for 6 days. Animals were allowed to stay on the platform for 10 s after each trial. Animals were then removed from the tank, dried and kept warm by using a heating pad and infrared light. The time to find the platform (escape latency; in seconds) and a description of the path followed in the tank were recorded and analyzed. As a further control, on day 6, the platform was moved to the diagonally opposite quadrant and another trial block (probe trial block) was performed. Following the last trial, animals were anesthetized and perfused with 50 ml saline followed by 50 ml phosphate buffered 10% formalin via cardiac catheter. All brains and major organs were then prepared for conventional histopathological analysis.
In vivo studies in an orthotopic brain metastasis model in nude mice
The efficacy of reovirus in treating breast cancer brain metastases was tested by establishing breast cancer xenografts in the putaman of nude mice and delivering i.t. reovirus. Two human breast cancer cell lines (HTB129 1 Â 10 6 cells/mouse; HTB132 1.5 Â 10 6 cells/mouse) were used. The stereotactic techniques used to implant these in the right putamen have been described elsewhere. 24, 25 Briefly, mice were anesthetized, a burr hole drilled 1.5-2 mm right of the midline and 0.5-1 mm posterior to the coronal suture through a scalp incision. A 5-ml syringe was used to inject 2-6 ml of cell suspension at a depth of 2-2.5 mm under guidance of a stereotactic frame (Kopf Instruments, Tujanga, CA, USA). After 12 days, when microscopic tumors grew and animals were asymptomatic, a single i.t. injection of 1 Â 10 7 PFUs PFUs of either LV or DV was administered stereotactically as above. For experiments to assess tumor size, animals were killed 54 days (an arbitrary time point) after tumor implantation. To kill them, animals were anesthetized, perfused intracardially with PBS and then fixed with 4% paraformaldehyde. All of the brains and major organs were examined histologically. Animals losing X20% of their body weight or having trouble ambulating, feeding, or grooming were killed. For experiments assessing survival, animals were monitored for 352 days when we arbitrarily terminated the experiment. All the animal experiments were carried out in accordance with the Care and Use of Experimental Animals Guide issued by Canadian Council on Animal Care.
In vivo studies in an immunocompetent model of leptomeningeal metastasis from breast cancer
To determine if reovirus prolonged survival in a model of leptomeningeal metastasis and to test reovirus' oncolytic capability in an immunocompetent host, we used a racine model of breast cancer leptomeningeal metastasis. 40 Viable breast cancer cells were harvested, washed and resuspended in PBS before implantation. Female Fischer 344 rats under anesthesia (40 mg/kg ketamine and 8 mg/kg xylazine, intraperitoneal (i.p.)) were fixed to a stereotactic apparatus with their head and neck bent to an angle of À1201 in order to fully expand the cisterna. An incision (1.5-2 cm) was made over the cerebellum and inferiorly to C1. The ligament between the skull and C1 was then exposed via blunt dissection. A syringe with a 30 G needle was used for tumor cell and virus injection. A volume of 50 ml of cerebrospinal fluid (CSF) was withdrawn prior to cell/virus administration to ensure the needle was in the cisterna magna. The wound was closed using a Wound Auto Clip Kit (Becton Dickinson, USA). Both tumor cells and virus were injected intrathecally. Virus (2 Â 10 9 PFU/rat) injection was given twice, 4 and 8 days after tumor inoculation, respectively. Animals were closely followed after surgery and killed using the same criteria as above. Brains, spinal cords and the major organs (ie heart, liver, lungs, and kidneys) were harvested and stored in 10% formalin.
To facilitate identification of tumor dissemination within the CSF, we labeled 13762MATBIII cells with GFP prior to intrathecal inoculation. A whole body fluorescence imaging system (WBFIS) was used to visualize CSF dissemination. The WBFIS uses a blue light fiber optics (Illumatool Tunable lighting system LT-9500, Encinitas, CA, USA), with a 190 W cool light Reovirus and breast cancer brain metastasis WQ Yang et al source, a 470/480 nm optic filter cup and a 515 nm view filter. 41, 25 For the local or high-magnification imaging, a Leica MZ-FLIII fluorescence stereomicroscope equipped with 100-W mercury-vapor burner and mounted with a Kodak DC 2900 digital camera was used. Images were processed and analyzed by using Photoshop 6.0 and Image-Pro Plus software.
Statistical analyses
Statistical Analysis Software (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism (version 4) (GraphPad Software Inc., San Diego, CA, USA) were used for statistical analyses. Survival curves were generated by the Kaplan-Meier method. The log-rank and MannWhitney tests were used to compare the distributions of survival times and tumor sizes, respectively. Fisher's exact test was used to analyze categorical data of tumor dissemination. The average latency data were analyzed with the ANOVA two-way test. All reported P-values were two-sided and were considered to be statistically significant at Po0.05.
Results
Susceptibility of breast cancer cells to reovirus infection in vitro
We examined the susceptibility of eight established (seven human and one racine) breast cancer cell lines and two cell lines derived from normal breast epithelium to reovirus infection. Dramatic and widespread cell killing after exposure to LV (but not DV) occurred in all of the breast cancer cell lines tested. The cytopathic effect was obvious for breast cancer cells 48 (or 72) h after cells were infected with live reovirus (Figure 1a ; not all lines are shown). In contrast, cells receiving DV or no virus (data not shown) and cells derived from normal breast epithelium (HTB124 and HTB125) remained healthy. To ensure that all lysis was due to viral replication, immunofluorescence using a polyclonal reovirus antibody was performed (Figure 1b) . Susceptible lines expressed reovirus proteins whereas nonsusceptible lines (eg HTB124 and HTB125) did not. To further confirm replication of reovirus in susceptible lines we used metabolic labeling with [ 35 S]methionine.
Lysates were immunoprecipitated with a polyclonal reovirus antibody and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A substantial amount of reovirus protein was synthesized 24 h after infection in susceptible lines with the exception of HTB19 where significant levels of viral protein synthesis was seen by 48 h (Figure 1c) . Little or no viral protein synthesis was observed in normal breast cell lines HTB125 (Figure 1c ) and HTB124 (data not shown). Examination of the brains of mice that died (ie treated with 10 9 PFUs/mouse) showed both local changes at the site of viral inoculation and wide spread changes. At the site of inoculation, major inflammatory changes with prominent lymphocytes, microglia and macrophages were found within a focal area of necrosis. Widespread changes observed were consistent with severe and diffuse encephalitis. All animals that died (treated with 10 9 PFUs i.c.) had very dilated ventricles, wide spread infiltration of inflammatory cells and marked cellular changes most prominent in the dentate gyrus and hippocampus (data not shown).
Mild histological changes and no behavioral abnormalities were found in nude mice treated with therapeutically effective doses of reovirus (ie p10 8 PFUs)
Local inflammation as well as mild communicating hydrocephalus was observed histologically in LV-treated (Figure 2a and b) but not in the DV-treated or control (ie nonoperated) animals. There was no obvious 'doseresponse' comparing 10 7 to 10 8 PFUs in terms of local inflammation. Calcification, local tissue reaction and activated cellular responses (microglia, macrophage, lymphocyte, etc.) mostly appeared around the injection site. No aqueductal obstruction or obstruction elsewhere in the CSF pathways was found in animals with hydrocephalus; we therefore designated this 'communicating' hydrocephalus. The brains of DV-treated or control animals were normal. To further characterize any diffuse inflammatory response (not evident in H&E staining), we examined brains after staining for GFAP and no difference was found between DV-and LVtreated brains even in brain regions such as hippocampus (data not shown). Sections were also stained for reovirus via immunohistochemistry but no virus was detected 60 days after virus infection (data not shown).
Morris water maze testing showed that all animals (ie in the normal, nonoperated controls, DV and LV groups) had similar performances and went through a regular learning curve. The latency to finding the submerged platform decreased for all groups over five trial blocks and, appropriately increased during the sixth block when the platform was moved. No difference was found in average latency between normal, DV-and LV-treated groups (two-way ANOVA test, P ¼ 0.876) (Figure 2c ). The experiment was repeated and similar results were obtained both times. 7 PFUs/ mouse (n ¼ 6) or 10 8 PFUs/mouse (n ¼ 7) LV-treated mice. Each trial block represents the average of four individual trials. There was no difference in the performance between groups (two-way ANOVA test P ¼ 0.876). As a control, after the fifth trial block, the platform was placed in the diagonally opposite quadrant and as expected an increase in latency occurred in all four groups.
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Reduced size of brain metastasis from human breast cancer in nude mice treated with reovirus
We investigated whether reovirus was effective against human breast cancer brain metastasis in two animal models. Nude mice were implanted i.c. with the human breast cancer cell lines HTB129 and HTB132 and reovirus was administered i.t. 12 days later when the xenograft was established. Dramatic tumor shrinkage was found using both cell lines. For example, in HTB129 xenografts, analyzed 42 days after the single administration of virus, the average tumor size (0.65% of cross-sectional brain area) was significantly smaller in the LV group than in the DV group (11.2% of cross-sectional brain area;
Mann-Whitney test, P ¼ 0.007) (Figure 3a bar graph) . In addition, metastastic lesions were found in the ventricles, the opposite hemisphere of the brain and along the leptomeninges only in DV animals (Figure 3a representative pictures are shown). In contrast, tumors in the LV group remained localized and no metastases in the brain or leptomeninges were found (Fisher's exact test, P ¼ 0.0006). LV-treated animals remained healthy and gained body weight whereas 2/7 (28%) DV-treated mice lost over 30% of their body weight or developed neurological symptoms requiring euthanasia. Six of seven (85%) DV-treated mice had a grossly visible tumor mass (often very large) whereas only one of seven (14%) Figure 3 Reovirus significantly reduced tumor size and local spread of human breast cancer in the brains of nude mice. Tumor-bearing mice were given a single reovirus injection i.t. 12 days after tumor inoculation. Tumor size was compared 42 days after infection. (a) Tumor size comparison between LV-and DV-treated mice with a HTB129 xenograft. Top: large and grossly visible tumor masses were found in all DV-treated mice and tumor dissemination in the ventricles (arrows), leptomeninges and the opposite hemisphere was found in DV-treated mice. In contrast, only microscopic or very small tumors mixed with calcification (arrow head) were found in LV-treated mice. No leptomeningeal or ventricular spread was found in LV-treated mice. Lower: average tumor area of DV-versus LV-treated groups (error bars represent standard error; DV n ¼ 7; LV n ¼ 7). On average, the tumors occupied 11.2% of the whole brain of DV-treated mice and 0.6% of LV-treated group (Mann-Whitney test Po0.007). Immunohistochemical staining for reovirus proteins was also performed to confirm that tumor regression was due to virus within the tumor xenografts. Staining of paraffin embedded sections showed reovirus proteins were present in LV-, but not DV-treated tumors ( Figure  3c ). Virus staining was not observed in regions of the brain remote from the site of inoculation (data not shown).
Large tumors with proliferating tumor cells and leptomeningeal spread were found in all DV-treated animals. In contrast, no metastatic tumor cells were found in the leptomeninges and only one mouse had a grossly visible tumor mass (though it was quite small) in the LV-treated group. Only local mild inflammatory changes and focal calcifications were found in most LVtreated animals (Figure 3d ). There was no histologic evidence of diffuse encephalitis in LV-treated mice.
Survival following the i.t. inoculation of reovirus into brain metastases from human breast cancer in nude mice is prolonged
We assessed the survival of nude mice harboring human breast cancer brain metastases treated with a single i.t. inoculation of LV (10 7 PFUs) administered 12 days after tumor implantation. HTB129 tumor-bearing animals treated with LV had longer survivals than DV-treated animals (Log rank test, Po0.0001). The median survival of DV-treated animals was 98 days, in contrast to 164 days in LV-treated animals (Figure 4a ). Furthermore, 2/10 (20%) of the LV-treated mice were 'long-term' survivors and survived 4320 days following tumor implantation. Similar results were found using the implantation of the human breast cancer cell line HTB132 in which LV-treated animals lived significantly longer than DV-treated animals (Figure 4b ) (Log rank test, P ¼ 0.001). The median survival of DV-treated animals was 69 days compared to 161 days in LV-treated animals. Again, 2/9 or 22% were 'long-term' survivors and survived 4290 days following tumor implantation.
Histologic examination showed that, for mice harboring the HTB129 tumors, 5/5 (100%) of DV-treated animals examined had large tumors and/or had metastasized locally to the brain parenchyma or leptomeninges. Eight of ten (80%) LV-treated mice had brain tumors and two of these eight (25%) had only microscopic tumor on histologic examination. One LV-treated mouse died of diabetes on day 162 and no tumor was found in its brain. Similarly, the long-term survivor (ie the one killed on day 352 when the experiment was terminated) had no histological evidence of tumor and was considered as 'cured'. Four of five (80%) of the DV-treated mice had invasive tumor spread to the leptomeninges and ventricles and 4/10 (40%) of the LVtreated animals had ventricular and leptomeningeal tumor spread (Fisher's exact test, P ¼ 0.143). For mice harboring the HTB132 tumor, 7/7 (100%) DV-treated mice examined had large brain tumors and all (100%) animals had tumor spread into different areas of the brain including the ventricles and leptomeninges. Six of seven (85.7%) LV-treated mice examined also died from tumor growth or tumor spread and three (42.8%) of these had tumor dissemination throughout the leptomeninges (Fisher's exact test, P ¼ 0.018). No tumor or leptomeningeal tumor was found in the long-term survivor. Again, mild inflammation and local tissue reaction was found in the areas of tumor/viral inoculation in tumor free mice in the LV group (Figure 4c) . Reovirus protein was detected within residual tumor cells that infiltrated in the inflammatory areas 100 days after infection (Figure 4d ).
Survival is prolonged after intrathecal administration of reovirus in a model of leptomeningeal breast cancer in immunocompetent rats
Since leptomeningeal metastases are another significant clinical problem in breast cancer and a functional immune system may limit the efficacy of oncolytic viruses, we evaluated the intrathecal administration of reovirus in an immunocompetent model of leptomeningeal metastasis from breast cancer. The median survival was significantly longer in LV-(16 days) compared to DV-treated animals (10 days) (Log rank test, Po0.0001) (Figure 5a ) though all LV-treated animals died from progressive leptomeningeal tumor. To further confirm the efficacy and to better visualize isolated tumor cells in the leptomeninges, we repeated the above experiment with GFP-labeled breast cancer cells (13762MATBIII-GFP). Again, survival was significantly pronged in LVtreated animals compared to the DV group (median survival 18 days versus 13 days) (Log rank test, Po0.0001) (Figure 5b) .
We examined the leptomeningeal lesions under fluorescence to facilitate the identification of isolated tumor cells. Scattered deposits of tumor cells were found in the ventricles, brain stem, cerebellum, medulla, subarachnoid space and spinal cord in all LV-and DVtreated animals (Figure 5c ). Only sparse tumor cells were found around the thoracic and lumbar spinal cord. No systemic (ie extraneural) metastases were found in either group.
Discussion
In this report, we examined the potential usefulness of reovirus to treat brain and leptomeningeal metastases from breast cancer. We found that reovirus inhibited growth of i.c. implanted breast cancer xenografts in nude mice, produced long-term survivors and decreased the incidence of leptomeningeal metastasis. In addition, we found reovirus was safe and effective in prolonging survival of immunocompetent animals with leptomeningeal metastasis. These data suggest that reovirus should be evaluated as an experimental therapeutic for parenchymal and leptomeningeal metastases from breast cancer.
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The use of oncolytic viruses to specifically target brain metastases is a novel strategy and only one other oncolytic virus (herpes simplex) has been evaluated using this approach. One study 11 used human breast cancer in nude mice and the other 12 used murine melanoma in immunocompetent animals. In both studies tumor growth was inhibited, survival was prolonged but long-term survivors were rare. As in our study, evidence of diffuse encephalitis at therapeutically effective doses was not found. 12 Therefore, the use of two different oncolytic viruses shows evidence of activity in experimental models of brain metastases from breast cancer. Outside of these general observations we cannot comment on comparisons between viruses because of differences in experimental techniques. The final proof of efficacy and toxicities awaits a clinical trial to test this in patients.
Our interest in using reovirus as a potential treatment for breast cancer metastasis was based on several observations. First, it is well established that activation or upregulation of Ras is important for the pathogenesis of breast cancer. And reovirus infects and kills cancer cells with activated Ras-signaling pathways. 19, 22 For instance, Her-2 (Neu/ErbB-2), a member of the EGFR family, is amplified and overexpressed in 430% of breast tumors. 31, 32 EGFR itself and the nonreceptor tyrosine kinase Src have also been implicated 34, 35, 42, 43 in breast cancer. These findings emphasize the importance of the Ras-signaling pathways in breast cancer and suggest that breast cancer would be a permissive cellular environment for reovirus oncolysis. Secondly, we have previously shown the effectiveness of reovirus oncolysis in breast cancer cell lines both in vitro and in a murine mammary tumor model. 23 And finally, strategies to block upstream activators of the Ras pathway (eg Her-2/Neu) are useful treatments in breast cancer and a number of other agents which target this pathway are currently being evaluated. 44, 45 Oncolysis with reovirus could be an We also show that reovirus inhibits leptomeningeal tumor growth and prolongs survival in immunocompetent hosts (though all animals eventually died from progressive tumor). This is important in general because it is easier to cure cancer in immunocompromised models of human cancer but more difficult in animals with intact immune systems. Theoretically, the immune system could have beneficial or detrimental effects. For example, an oncolytic virus could activate the immune system and enhance cell killing; a beneficial effect. Or the immune response could limit the spread of oncolytic viruses and their ability to infect and kill tumor cells remote from the site of administration. Manipulation of the immune response, for example with cyclosporine A, anti-CD4/anti-CD8 or complement neutralization, does improve the efficacy of some oncolytic viruses in targeting remote/metastatic tumors. 46, 27 So while we are encouraged by our results in this study, experiments are underway to determine if we can enhance tumor killing in immunocompetent animals using similar approaches.
Although reovirus is a naturally occurring virus, the safety and toxicity of the i.c. inoculation of this replication competent virus has not been systematically studied. To begin to evaluate the safety of intracerebrally administered reovirus we examined brain structure (using standard histology) and function (using the MWMT). When using therapeutically effective doses there was moderate inflammation at the site of viral innoculation and mild communicating hydrocephalus with subependymal inflammation. No diffuse inflammatory response or evidence of viral encephalitis (using morphology or immunohistochemistry; viral cultures were not performed) was found. Similarly, mice treated with 10 7 or 10 8 PFUs appeared to be healthy, gained weight and learned normally in the MWMT. As expected, however, with virtually any cancer treatment, reovirus was also lethal in large enough doses. In all, 75% of animals treated intracerebrally with the highest dose of reovirus (the highest dose feasible to prepare/ Reovirus and breast cancer brain metastasis WQ Yang et al administer (10 9 PFUs)) died from diffuse encephalitis. Overall we were encouraged by our results at appropriate doses but definitive comments regarding its safety await the results of primate studies and, ultimately, clinical trials.
This work has several limitations. First, brain metastases originate from hematogenously disseminated tumor cells and the models (ie direct implantation via intracerebral or intrathecal inoculation) we used do not prove this would be effective against brain metastases spread in this manner. Second, we were unable, because of a paucity of surgical specimens from brain metastases patients at our institution, to determine if the cell killing we observed was an artifact of the highly selected nature of established cell lines we used. To partially address this limitation, we did examine eight different breast cancer cell lines originating from different sources and found that all were susceptible. In addition, our previous work showed that reovirus infected and killed breast cancer cells derived from surgical specimens from the breast 23 ; though only three biopsy samples were studied. Further studies are needed to determine whether most surgical samples of brain metastases from breast cancer are susceptible to reovirus and whether ex vivo susceptibility correlates with therapeutic efficacy in a clinical setting. Third, the mechanism of cell death in breast cancer induced by reovirus has not yet been fully determined. At least two breast cancer cell lines (eg ZR75-1 and MDA-MB231) undergo apoptosis after reovirus infection in response to TRAIL released from the infected cells. 47 It remains to be determined whether reovirus kills all breast cancer derived brain metastasis via apoptosis, direct cell lysis or both. Other mediators or pathways including death receptors, NF-kB, caspase cascades, TNF-related apoptosis-inducing ligand (TRAIL) and JNK/c-Jun have been reported to be involved in reovirus induced cell death. [48] [49] [50] [51] [52] Lastly, the safety/toxicity studies performed in this report used reovirus prepared from our laboratory stocks that could contain contaminants. Evaluation of the potential toxicity of i.c. administration of reovirus prepared in a GMP environment will be required before this is considered for a clinical trial.
We investigated the use of reovirus as an oncolytic agent in various models of brain and leptomeningeal metastases from breast cancer. We found that it had a potent effect against experimental CNS metastases from breast cancer. Reovirus is currently being evaluated in several clinical trials, 53 including a phase I/II study in patients with recurrent malignant gliomas (P.F. is P.I).
